Thursday July 22, 7:00 am Eastern Time
Company Press Release
SOURCE: Affymetrix, Inc.
Six National Institutes of Health (NIH) Institutes Gain
Broad Access To Affymetrix GeneChip(R)
Technology
SANTA CLARA, Calif., July 22 /PRNewswire/ -- Affymetrix, Inc. (Nasdaq: AFFX - news) announced today that it has
entered into a broad GeneChip technology access agreement with six participating institutes of the National Institutes of
Health (NIH). The participating institutes include: the National Cancer Institute (NCI), the National Heart, Lung and
Blood Institute (NHLBI); the National Institute of Allergy and Infectious Diseases (NIAID); the National Institute of
Arthritis and Musculoskeletal and Skin Diseases (NIAMSD); the National Institute of Child Health and Human
Development (NICHD) and the National Institute of Health Clinical Center (NIHCC).
Under the agreement announced today, researchers at the NIH will gain broad access to Affymetrix' standard and
custom GeneChip© arrays, instrumentation and software to monitor gene expression for use in their research activities.
The agreement includes terms and conditions for use of the GeneChip technology, volume discounts and minimum
purchase commitments. The terms and conditions for use of the GeneChip technology by NIH researchers have been
specially designed to allow for broad publication of scientific results and to facilitate collaborations with academic,
governmental, and commercial scientific colleagues.
``As the Federal Government's principal agency for biomedical research, the NIH is a pioneering force in the academic
community and we are delighted to have them as our latest customer,' said Stephen P.A. Fodor, Ph.D., President and
Chief Executive Officer of Affymetrix. ``NCI's support in helping us develop terms and conditions that are consistent
with their research policies has been invaluable to our efforts to structure broader access programs that meet the needs
of other not-for profit researchers.'
Affymetrix has developed and intends to establish its GeneChip system as the platform of choice for acquiring, analyzing
and managing complex genetic information in order to improve the diagnosis, monitoring and treatment of disease. The
Company's GeneChip system consists of disposable DNA probe arrays containing gene sequences on a chip, reagents
for use with the probe arrays, a scanner and other instruments to process the probe arrays and software to analyze and
manage genetic information. Additional information on Affymetrix and GeneChip technology can be found at
www.affymetrix.com.
All statements in this press release that are not historical are forward-looking statements. Such statements are subject to
risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected, including,
but not limited to, uncertainties relating to technological approaches, product development, manufacturing, and market
acceptance, uncertainties related to cost and pricing of Affymetrix products, dependence on collaborative partners,
uncertainties relating to sole source suppliers, uncertainties relating to FDA and other regulatory approvals, competition,
risks relating to intellectual property of others and the uncertainties of patent protection. These and other risk factors are
discussed in Affymetrix' Form 10-K Report for the year ended December 31, 1998, Form 10-Q for the quarter ended
March 31, 1999 and Form S-3 filed July 12, 1999. Affymetrix expressly disclaims any obligation or undertaking to
release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in
Affymetrix' expectations with regard thereto or any change in events, conditions, or circumstances on which any such
statements are based. Affymetrix, GeneChip and the Affymetrix logo are registered trademarks used by Affymetrix, Inc.
SOURCE: Affymetrix, Inc. |
